{"analyses":[{"ciLowerLimit":"2.5","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"12.4","estimateComment":"Mean difference \\>0 favours olaparib.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0035","paramType":"Mean Difference (Final Values)","paramValue":"7.5","statisticalComment":"Variables for treatment, visit, treatment-visit interaction, adjusted for baseline global health status/QoL score, baseline score-visit interaction.","statisticalMethod":"Mixed Models Analysis"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.5","upperLimit":"6.3","value":"3.9"},{"groupId":"OG001","lowerLimit":"-8.0","upperLimit":"0.8","value":"-3.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"191"},{"groupId":"OG001","value":"73"}],"units":"Participants"}],"description":"Change from baseline in global health status/quality of life (QoL) score assessed using a mixed model for repeated measures (MMRM) analysis, including all post-baseline global health status/QoL scores up to the latest scheduled visit where at least 20 patients on each treatment arm have a score. Global health status/QoL score is on a scale from 0 to 100. A higher score represents an improved health status/QoL.","dispersionType":"95% Confidence Interval","groups":[{"description":"Olaparib 300 mg bd tablets","id":"OG000","title":"Olaparib 300 mg bd"},{"description":"Physician's choice of chemotherapy; capecitabine, vinorelbine, or eribulin","id":"OG001","title":"Chemotherapy"}],"paramType":"MEAN","populationDescription":"Subset of Full Analysis Set (FAS) consisting of all randomised patients with an evaluable baseline EORTC QLQ-C30 assessment and at least one evaluable post-baseline assessment","reportingStatus":"POSTED","timeFrame":"EORTC QLQ-C30 assessments performed at baseline then every ~6 weeks until objective radiological disease progression. Assessed up to a maximum of 30 months.","title":"Adjusted Mean Change in Global Health Status/Quality of Life (QoL) Score From the European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire (EORTC QLQ-C30)","type":"SECONDARY","unitOfMeasure":"Score on a scale"}